Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives
Yan Li, Jian H. Song, Ping Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10183-10194
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC
Miao Chen, Ping Zhou, Yun Kong, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 2, pp. 1339-1348
Closed Access | Times Cited: 35
Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 27
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 24
Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy
Jing Huang, Zhuo Yao, Bowen Li, et al.
Journal of Controlled Release (2023) Vol. 361, pp. 270-279
Closed Access | Times Cited: 21
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 20
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Lingping Kong, Fanlu Meng, Ping Zhou, et al.
Science Bulletin (2024) Vol. 69, Iss. 13, pp. 2122-2135
Open Access | Times Cited: 8
Targeted Degradation of HCV Polymerase by GalNAc-Conjugated ApTACs for Pan-Genotypic Antiviral Therapy with High Resistance Barriers
Wei Pan, Sijin Wu, Honglin Zhou, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
PROTACs coupled with oligonucleotides to tackle the undruggable
Guangshuai Zhang, Si Yan, Yan Liu, et al.
Bioanalysis (2025), pp. 1-16
Closed Access
Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC
Lingping Kong, Fanlu Meng, Sijin Wu, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 2
Open Access | Times Cited: 18
Peptide-based PROTACs: Current Challenges and Future Perspectives
Huidan Wang, Miao Chen, Xiaoyuan Zhang, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 2, pp. 208-222
Closed Access | Times Cited: 14
Targeted protein degradation in drug development: Recent advances and future challenges
Jian H. Song, Mingzheng Hu, Jun Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115839-115839
Closed Access | Times Cited: 14
Transcription factors in fibroblast plasticity and CAF heterogeneity
Roberta Melchionna, Paola Trono, Anna Di Carlo, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 14
Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein
Yuchun Wang, Gang Yang, Xinyu Zhang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Closed Access | Times Cited: 5
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Paul A. Meyers, Noah Federman, Najat C. Daw, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3725-3734
Closed Access | Times Cited: 5
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Advances of bioorthogonal coupling reactions in drug development
Feiyan Zhan, Jingjie Zhu, Shaowen Xie, et al.
European Journal of Medicinal Chemistry (2023) Vol. 253, pp. 115338-115338
Closed Access | Times Cited: 13
Targeted degradation of membrane and extracellular proteins with LYTACs
Yuyang Li, Yang Yang, Renshuai Zhang, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 3
Rational drug design targeting intrinsically disordered proteins
H. Wang, Ruoyao Xiong, Luhua Lai
Wiley Interdisciplinary Reviews Computational Molecular Science (2023) Vol. 13, Iss. 6
Closed Access | Times Cited: 10
Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1
Tiantian Wang, Lidan Pang, Mengni He, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115889-115889
Closed Access | Times Cited: 8
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Qiong Li, Li Zhou, Siyuan Qin, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115447-115447
Closed Access | Times Cited: 6
RIPTACs: A groundbreaking approach to drug discovery
Zonghui Ma, Andrew A. Bolinger, Jia Zhou
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103774-103774
Open Access | Times Cited: 6
Transcription Factors and Cancer
Jamie V. Shiah, Daniel E. Johnson, Jennifer R. Grandis
The Cancer Journal (2023) Vol. 29, Iss. 1, pp. 38-46
Closed Access | Times Cited: 5
Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions
Tongqing Li, Xueying Liu, Haifeng Qian, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras
Chen Zhou, Chunbao Sun, Miao Huang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15168-15198
Closed Access | Times Cited: 1
Development of natural product-based targeted protein degraders as anticancer agents
Cheng Chen, Yanyan Feng, Chen Zhou, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107772-107772
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top